Premium
HIF‐1α and CA‐IX as predictors of locoregional control for determining the optimal treatment modality for early‐stage laryngeal carcinoma
Author(s) -
Kwon Oh Jin,
Park Jung Je,
Ko Gyung Hyuck,
Seo Ji Hyun,
Jeong BaeKwon,
Kang Ki Mun,
Woo Seung Hoon,
Kim Jin Pyeong,
Hwa Jeong Seok,
Carey Thomas E.
Publication year - 2015
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.23620
Subject(s) - immunohistochemistry , erythropoietin receptor , stage (stratigraphy) , medicine , radiation therapy , carcinoma , oncology , laryngeal neoplasm , pathology , erythropoietin , biology , paleontology
Background The purpose of this study was to examine the predictive value of hypoxia‐inducible factor (HIF)−1α, carbonic anhydrase (CA)‐IX, glucose transporter (GLUT)−1, cyclooxygenase (COX)−2, Ki‐67, and erythropoietin receptor (EPOR) as immunohistochemical markers for determining the optimal treatment modality for early stage laryngeal carcinoma. Methods Tissue samples from 42 early stage laryngeal carcinomas treated with radiotherapy alone were analyzed immunohistochemically for the expression of 6 markers. The Kaplan–Meier method, univariate and multivariate analyses, and the Cox proportional hazards model were used to analyze the associations between patient and tumor characteristics and immunohistochemical results, and locoregional control. Results Increased expression of HIF‐1α and CA‐IX was significantly correlated with residual tumor; no correlations were observed for the other immunohistochemical markers. Conclusion High levels of HIF‐1α or CA‐IX expression were significantly correlated with residual tumor after radiotherapy for early stage laryngeal carcinomas. Alternative treatment modalities to primary radiotherapy should be considered for early stage laryngeal carcinomas showing high HIF‐1α or CA‐IX expression. © 2014 Wiley Periodicals, Inc. Head Neck 37 : 505–510, 2015